Results 271 to 280 of about 187,113 (345)

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source

The inflammatory index and cytokines are associated with non-alcoholic fatty liver disease in type 2 diabetes mellitus. [PDF]

Front Med (Lausanne)
Liu R, Liu R, Liu M, Tian Y, Liu J, Wang Y, Sui Q, Zhang J, Xu H, Qi Z.   +9 more
europepmc   +1 more source

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

Clinical Pharmacology &Therapeutics, EarlyView.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen, Jeffrey L. Woodhead, Brett A. Howell, Lisl K. M. Shoda, Dolly A. Parasrampuria, Jiayin Huang, Megumi Iwai, Faith D. Ottery, Xuegong Wang, Marci English, Kentaro Miyazaki, Paul B. Watkins   +11 more
wiley   +1 more source

Targeting the intestinal barrier with traditional Chinese medicine for non-alcoholic fatty liver disease: mechanistic insights and therapeutic perspectives. [PDF]

Chin Med
Cheng X, Li S, Huang C, Yang Y, Liu R, Cao S, Luo L, Lu B.   +7 more
europepmc   +1 more source

Efficacy of Vitamin E Versus Pioglitazone in Treating Non-Alcoholic Fatty Liver Disease (NAFLD) without Diabetes “Decoding the Exodus of Liver Health”.

Muhammad Owais Fazal, Ghulam Abbas Tahir, Yasir Yaqoob, A. Zeeshan, Rabia Sharif, Muhammad Usman Musharraf   +5 more
openalex   +2 more sources

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Frequency of Gallstones in Patients With Non-alcoholic Fatty Liver Disease. [PDF]

Cureus
Soomro U, Abbas G, Aslam M, Kirshan Kumar S, Hyder A, Tareen K, Ahmed I, Taha Yaseen Khan R, Hassan Luck N.   +8 more
europepmc   +1 more source

Correlation between non-alcoholic fatty liver disease and metabolic parameters in persons with newly diagnosed type 2 diabetes mellitus

Supriyo Mukherjee, Sushmita Mukherjee, Chun Shing Kwok, Anne Phillips   +3 more
openalex   +1 more source

The Association between Angiotensin II Type 1 Receptor Gene A1166C Polymorphism and Non-alcoholic Fatty Liver Disease and Its Severity

, 2018
Ahad Eshraghian, Shahrokh Iravani, Pedram Azimzadeh   +2 more
openalex   +2 more sources

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source